MA29027B1 - Procedes de renaturation d'anticorps recombinants - Google Patents

Procedes de renaturation d'anticorps recombinants

Info

Publication number
MA29027B1
MA29027B1 MA29914A MA29914A MA29027B1 MA 29027 B1 MA29027 B1 MA 29027B1 MA 29914 A MA29914 A MA 29914A MA 29914 A MA29914 A MA 29914A MA 29027 B1 MA29027 B1 MA 29027B1
Authority
MA
Morocco
Prior art keywords
methods
recombinant antibodies
renaturing
renaturing recombinant
antibodies
Prior art date
Application number
MA29914A
Other languages
English (en)
Inventor
Thomas Dillon
Douglas Rehder
Pavel Bondarenko
Margaret Ricci
Himanshu S Gadgil
Douglas Banks
Joe Zhou
Yuefeng Lu
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36129791&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA29027(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MA29027B1 publication Critical patent/MA29027B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39516—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum from serum, plasma
    • A61K39/39525—Purification
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MA29914A 2004-10-22 2007-05-17 Procedes de renaturation d'anticorps recombinants MA29027B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62129504P 2004-10-22 2004-10-22
US70176205P 2005-07-22 2005-07-22

Publications (1)

Publication Number Publication Date
MA29027B1 true MA29027B1 (fr) 2007-11-01

Family

ID=36129791

Family Applications (1)

Application Number Title Priority Date Filing Date
MA29914A MA29027B1 (fr) 2004-10-22 2007-05-17 Procedes de renaturation d'anticorps recombinants

Country Status (16)

Country Link
US (1) US7928205B2 (fr)
EP (1) EP1805320B1 (fr)
JP (2) JP5553963B2 (fr)
KR (1) KR101370253B1 (fr)
AU (1) AU2005299716B2 (fr)
BR (1) BRPI0517457A (fr)
CA (1) CA2584211C (fr)
EA (1) EA012162B1 (fr)
IL (1) IL182626A0 (fr)
MA (1) MA29027B1 (fr)
MX (1) MX2007004437A (fr)
NO (1) NO20072571L (fr)
NZ (1) NZ554520A (fr)
RU (1) RU2007118954A (fr)
SG (1) SG156672A1 (fr)
WO (1) WO2006047340A2 (fr)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG156672A1 (en) * 2004-10-22 2009-11-26 Amgen Inc Methods for refolding of recombinant antibodies
AU2006232287B2 (en) 2005-03-31 2011-10-06 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
US7476852B2 (en) * 2005-05-17 2009-01-13 Honeywell International Inc. Ionization-based detection
MX2007014148A (es) * 2005-05-19 2008-01-11 Amgen Inc Composiciones y metodos para incrementar la estabilidad de anticuerpos.
EP2009101B1 (fr) 2006-03-31 2017-10-25 Chugai Seiyaku Kabushiki Kaisha Procede de modification d'anticorps pour purifier un anticorps bispecifique
EP4001409A1 (fr) * 2006-03-31 2022-05-25 Chugai Seiyaku Kabushiki Kaisha Procédés pour le contrôle de la pharmacocinétique sanguine d'anticorps
PE20081179A1 (es) * 2006-10-06 2008-09-29 Amgen Inc Formulaciones estables de anticuerpos egfr
US7705132B2 (en) * 2006-10-20 2010-04-27 Amgen Inc. Stable polypeptide formulations
AU2007338013A1 (en) * 2006-12-22 2008-07-03 Ares Trading S.A. Analytical method for analyzing C-terminus truncation
EP2626372B1 (fr) 2007-03-29 2018-03-21 Genmab A/S Anticorps bispécifiques et procédés de production de ceux-ci
CN101932591B (zh) 2007-07-09 2018-02-16 健泰科生物技术公司 在多肽的重组生产期间防止二硫键还原
WO2009036209A2 (fr) * 2007-09-14 2009-03-19 Amgen Inc. Populations d'anticorps homogènes
WO2009041621A1 (fr) 2007-09-26 2009-04-02 Chugai Seiyaku Kabushiki Kaisha Anticorps du récepteur anti-il-6
AU2016202036B2 (en) * 2007-09-26 2017-12-07 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant region
ES2595638T3 (es) 2007-09-26 2017-01-02 Chugai Seiyaku Kabushiki Kaisha Método para modificar el punto isoeléctrico de un anticuerpo mediante la sustitución de aminoácidos en una CDR
PE20090711A1 (es) * 2007-09-26 2009-07-15 Chugai Pharmaceutical Co Ltd Region constante de anticuerpo mutante
JP5682995B2 (ja) * 2007-12-05 2015-03-11 中外製薬株式会社 抗ｎｒ１０抗体、およびその利用
CA2718289A1 (fr) * 2008-03-12 2009-09-17 Imclone Llc Anticorps de l'antigene tyrp1
KR102084925B1 (ko) 2008-04-11 2020-03-05 추가이 세이야쿠 가부시키가이샤 복수 분자의 항원에 반복 결합하는 항원 결합 분자
JP5646457B2 (ja) * 2008-04-29 2014-12-24 アッヴィ・インコーポレイテッド 二重可変ドメイン免疫グロブリン及びその使用
EP3002299A1 (fr) * 2008-06-03 2016-04-06 AbbVie Inc. Immunoglobulines à deux domaines variables et leurs utilisations
KR20110016959A (ko) * 2008-06-03 2011-02-18 아보트 러보러터리즈 이원 가변 도메인 면역글로불린 및 이의 용도
AU2009268585C1 (en) * 2008-07-08 2014-10-02 Abbvie Inc. Prostaglandin E2 dual variable domain immunoglobulins and uses thereof
BRPI0917298B8 (pt) * 2008-08-19 2021-05-25 Glytech Inc método de produção de glicoproteína e método de rastreamento de glicoproteína
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
JP5787446B2 (ja) * 2009-03-19 2015-09-30 中外製薬株式会社 抗体定常領域改変体
JP5717624B2 (ja) 2009-03-19 2015-05-13 中外製薬株式会社 抗体定常領域改変体
CA2759370C (fr) 2009-04-30 2020-02-11 Peter Schotte Procede de production d'anticorps a domaines
KR20140014382A (ko) * 2009-05-01 2014-02-06 애브비 인코포레이티드 이원 가변 도메인 면역글로불린 및 이의 용도
JP5669732B2 (ja) 2009-05-15 2015-02-12 中外製薬株式会社 抗ａｘｌ抗体
BRPI1011940B8 (pt) 2009-06-22 2021-08-03 Amgen Inc método de redobramento de uma proteína expressa em um sistema de expressão de não mamífero
EP3660032A1 (fr) 2009-06-25 2020-06-03 Amgen, Inc Processus de purification de capture pour protéines exprimées dans un système non mammifère
UY32808A (es) * 2009-07-29 2011-02-28 Abbott Lab Inmunoglobulinas como dominio variable dual y usos de las mismas
WO2011037158A1 (fr) 2009-09-24 2011-03-31 中外製薬株式会社 Régions constantes modifiées d'un anticorps
EP2483289B1 (fr) 2009-10-02 2019-03-20 Biogen MA Inc. Procedes permettant de detruire et de reduire la formation de liaisons trisulfure
BR112012008833A2 (pt) * 2009-10-15 2015-09-08 Abbott Lab imunoglobulinas de dominio variavel duplo e usos das mesmas
UY32979A (es) * 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
EP2543730B1 (fr) 2010-03-04 2018-10-31 Chugai Seiyaku Kabushiki Kaisha Variante de région constante d'anticorps
AU2011244282A1 (en) 2010-04-20 2012-11-15 Genmab A/S Heterodimeric antibody Fc-containing proteins and methods for production thereof
MY160445A (en) 2010-08-03 2017-03-15 Abbvie Inc Dual Variable Domain Immunoglobulins And Uses Thereof
RU2013113225A (ru) 2010-08-26 2014-10-10 Эббви Инк. Иммуноглобулины с двумя вариабельными доменами и их применение
CN108715614A (zh) 2010-11-30 2018-10-30 中外制药株式会社 与多分子的抗原重复结合的抗原结合分子
PL2702164T3 (pl) 2011-04-29 2016-06-30 Biocon Res Limited Sposób obniżania heterogeniczności przeciwciał i sposób ich wytwarzania
WO2012158551A1 (fr) 2011-05-13 2012-11-22 Biogen Idec Ma Inc. Procédés pour prévenir et éliminer des liaisons trisulfure
DK2771364T3 (da) * 2011-10-27 2019-08-19 Genmab As Fremstilling af heterodimere proteiner
CA2857194A1 (fr) * 2011-12-07 2013-06-13 Thomas M. Dillon Separation d'isoforme de disulfure d'igg2
JP2015508994A (ja) 2011-12-30 2015-03-26 アッヴィ・インコーポレイテッド Ｉｌ−１３および／またはｉｌ−１７に対する二重可変ドメイン免疫グロブリン
CN104507955A (zh) * 2012-05-31 2015-04-08 新加坡科技研究局 采用具有多形式官能性的颗粒对免疫球蛋白g制备物的色谱纯化
KR20190096459A (ko) 2012-11-01 2019-08-19 애브비 인코포레이티드 항-ｖｅｇｆ／ｄｌｌ4 이원 가변 도메인 면역글로불린 및 이의 용도
CA2902854C (fr) 2013-03-08 2024-01-23 Genzyme Corporation Fabrication continue integree de substances de medicament de proteine therapeutique
MX2015013166A (es) 2013-03-15 2015-12-11 Abbvie Inc Proteinas de union especificas duales dirigidas contra il-1 beta y/o il-17.
KR20150134372A (ko) * 2013-03-29 2015-12-01 다이소 가부시키가이샤 세포 배양용 배지 첨가물
EP3030249B1 (fr) * 2013-08-07 2019-12-25 Rigshospitalet, Copenhagen University Hospital Anticorps, composés et dérivés associés destinés à être utilisés dans le traitement de l'infertilité masculine
CA2921999C (fr) 2013-09-13 2023-03-21 Genentech, Inc. Methodes et compositions comprenant un anticorps anti-il-13 et une phospholipase b-like 2 de hamster residuelle
EP3044323B1 (fr) * 2013-09-13 2022-04-06 F. Hoffmann-La Roche AG Méthodes de détection et de quantification d'une protéine cellulaire hôte dans des lignées cellulaires
WO2015046467A1 (fr) 2013-09-27 2015-04-02 中外製薬株式会社 Procédé de production d'un hétéromultimère polypeptidique
TWI709569B (zh) 2014-01-17 2020-11-11 美商健臻公司 無菌層析樹脂及其用於製造方法的用途
TWI709570B (zh) 2014-01-17 2020-11-11 美商健臻公司 無菌層析法及製法
KR102376287B1 (ko) 2014-04-02 2022-03-17 에프. 호프만-라 로슈 아게 다중특이적 항체 경쇄 잘못짝짓기의 검출 방법
US10647777B2 (en) 2014-05-28 2020-05-12 Genzyme Corporation Methods of controlling the formation of disulfide bonds in protein solutions
RS60631B1 (sr) 2014-11-21 2020-09-30 Bristol Myers Squibb Co Antitela protiv cd73 i njihova upotreba
PL3221346T3 (pl) 2014-11-21 2021-03-08 Bristol-Myers Squibb Company Przeciwciała ze zmodyfikowanym regionem stałym łańcucha ciężkiego
WO2016094881A2 (fr) 2014-12-11 2016-06-16 Abbvie Inc. Protéines de liaison à lrp-8
DK3233907T3 (da) 2014-12-19 2021-06-07 Genmab As Bispecifikke heterodimeriske proteiner hos gnavere
MX2017007670A (es) * 2014-12-22 2017-10-27 Ucb Biopharma Sprl Metodo de manufactura de proteina.
AR103172A1 (es) 2014-12-22 2017-04-19 Novartis Ag Reducción selectiva de residuos de cisteina en anticuerpos il-17
WO2016136933A1 (fr) 2015-02-27 2016-09-01 中外製薬株式会社 Composition pour le traitement de maladies associées à il-6
WO2016159213A1 (fr) 2015-04-01 2016-10-06 中外製薬株式会社 Procédé pour la production d'un hétéro-oligomère polypeptidique
GB201506869D0 (en) 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method
GB201506870D0 (en) 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
US11649262B2 (en) 2015-12-28 2023-05-16 Chugai Seiyaku Kabushiki Kaisha Method for promoting efficiency of purification of Fc region-containing polypeptide
US11312745B2 (en) * 2016-07-22 2022-04-26 Amgen Inc. Methods of purifying Fc-containing proteins
WO2018018613A1 (fr) 2016-07-29 2018-02-01 广东东阳光药业有限公司 Milieu de culture et procédé de culture cellulaires pour augmenter la pureté d'un anticorps
SG10201607778XA (en) 2016-09-16 2018-04-27 Chugai Pharmaceutical Co Ltd Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
WO2018203545A1 (fr) 2017-05-02 2018-11-08 国立研究開発法人国立精神・神経医療研究センター Procédé de prédiction et d'évaluation d'un effet thérapeutique dans des maladies associées à il-6 et à des neutrophiles
EP3672632A1 (fr) * 2017-08-22 2020-07-01 Biogen MA Inc. Compositions pharmaceutiques et schémas posologiques contenant des anticorps anti-alpha (v) bêta (6)
TW201923069A (zh) 2017-10-02 2019-06-16 美商拜耳保健有限責任公司 以亞硒酸鹽防止細胞培養收獲物中雙硫鍵還原之方法
CN111246885B (zh) 2017-10-20 2024-06-11 豪夫迈·罗氏有限公司 从单特异性抗体生成多特异性抗体的方法
CN111372947A (zh) 2017-10-30 2020-07-03 豪夫迈·罗氏有限公司 在体内从单特异性抗体产生多特异性抗体的方法
US11952422B2 (en) 2017-12-05 2024-04-09 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule comprising altered antibody variable region binding CD3 and CD137
US11447547B1 (en) 2017-12-13 2022-09-20 Amgen Inc. Method of antigen-binding protein production
US11891432B2 (en) 2018-03-15 2024-02-06 Chugai Seiyaku Kabushiki Kaisha Anti-dengue virus antibodies having cross-reactivity to Zika virus and methods of use
EA202092335A1 (ru) 2018-04-02 2021-01-22 Эмджен Инк. Композиции на основе эренумаба и пути их применения
KR20210045425A (ko) * 2018-08-15 2021-04-26 브리스톨-마이어스 스큅 컴퍼니 하류 크로마토그래피에서의 재산화에 의한 단백질 단편화 제어 전략
SG11202101860UA (en) 2018-08-31 2021-03-30 Genzyme Corp Sterile chromatography resin and use thereof in manufacturing processes
US10899826B1 (en) 2018-09-13 2021-01-26 Teva Pharmaceuticals International Gmbh Pharmaceutical compositions for an anti-CGRP antagonist antibody
AR117650A1 (es) * 2018-10-11 2021-08-18 Amgen Inc Procesamiento posterior de constructos de anticuerpos biespecíficos
EP4126970A4 (fr) 2020-03-31 2024-05-01 Chugai Seiyaku Kabushiki Kaisha Procédé de production de molécules multispécifiques de liaison à un antigène
EP4126969A4 (fr) 2020-03-31 2024-05-29 Chugai Seiyaku Kabushiki Kaisha Molécules multispécifiques de liaison à l'antigène ciblant dll3 et leurs utilisations
CA3192069A1 (fr) * 2020-09-14 2022-03-17 Michael Spector Methode de traitement de l'amylose
KR20240055101A (ko) * 2021-09-14 2024-04-26 시일럼 바이오사이언시즈, 인크. 다발성 골수종의 치료 방법

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) * 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4870009A (en) * 1982-11-22 1989-09-26 The Salk Institute For Biological Studies Method of obtaining gene product through the generation of transgenic animals
US4501728A (en) * 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
GB8308235D0 (en) * 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4745051A (en) * 1983-05-27 1988-05-17 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
US4952496A (en) * 1984-03-30 1990-08-28 Associated Universities, Inc. Cloning and expression of the gene for bacteriophage T7 RNA polymerase
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4766205A (en) * 1985-11-13 1988-08-23 Beatrice Companies, Inc. Method for isolation of recombinant polypeptides in biologically active forms
US4737323A (en) * 1986-02-13 1988-04-12 Liposome Technology, Inc. Liposome extrusion method
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4837028A (en) * 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
EP0293785A3 (fr) 1987-05-29 1990-05-02 Oncogen Limited Partnership Clonage et expression du facteur de croissance transformant simien SS-1
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5242687A (en) * 1989-03-15 1993-09-07 Tkb Associates Limited Partnership Method of reducing cellular immune response involving T-cells using CD8-bearing antigen presenting cells
US5272071A (en) * 1989-12-22 1993-12-21 Applied Research Systems Ars Holding N.V. Method for the modification of the expression characteristics of an endogenous gene of a given cell line
US5169784A (en) * 1990-09-17 1992-12-08 The Texas A & M University System Baculovirus dual promoter expression vector
US5266317A (en) * 1990-10-04 1993-11-30 University Of Georgia Research Foundation, Inc. Insect-specific paralytic neurotoxin genes for use in biological insect control: methods and compositions
DE4113750A1 (de) 1991-04-26 1992-10-29 Boehringer Mannheim Gmbh Verbesserung der renaturierung bei der sekretion von disulfidverbrueckten proteinen
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
US5243041A (en) * 1991-08-22 1993-09-07 Fernandez Pol Jose A DNA vector with isolated CDNA gene encoding metallopanstimulin
WO1993008207A1 (fr) 1991-10-25 1993-04-29 Immunex Corporation Nouvelle cytokine
AU648214B2 (en) 1991-12-31 1994-04-14 Lucky Limited Recombinant gene coding for human alpha interferon and expression vector thereof, etc.
AU6492194A (en) * 1993-04-01 1994-10-24 Schering Corporation (in vitro) refolding of recombinant fv fragments
WO1995032216A1 (fr) 1994-05-25 1995-11-30 University Of Nebraska Board Of Regents Hormones glycoproteiques biologiquement actives produites dans des cellules procaryotes
EP0766564A4 (fr) * 1994-06-24 1998-09-23 Immunex Corp Compositions a base de polypeptides et a liberation lente, et procedes de traitement des affections intestinales inflammatoires
HUT76666A (en) 1994-07-22 1997-10-28 Hoffmann La Roche Pharmaceutical compositions comprising a chimaeric tnf binding protein
DK0832229T3 (da) 1995-06-07 2004-05-03 Immunex Corp CD40L-mutein
US6063905A (en) * 1997-01-07 2000-05-16 Board Of Regents, The University Of Texas System Recombinant human IGA-J. chain dimer
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
FR2803303B1 (fr) 2000-01-04 2002-05-10 Aventis Pasteur Glycoproteine d'enveloppe du vih modifiee chimiquement
AUPQ599700A0 (en) * 2000-03-03 2000-03-23 Super Internet Site System Pty Ltd On-line geographical directory
CA2433353C (fr) 2000-12-28 2017-03-21 Altus Biologics, Inc. Cristaux d'anticorps entiers et fragments d'anticorps et methodes de fabrication et d'utilisation associees
CZ20032208A3 (cs) * 2001-02-23 2004-01-14 Immunex Corporation Zvýšený výtěžek aktivních proteinů
AU2002322295C1 (en) 2001-06-21 2008-12-18 Altus Pharmaceuticals Inc. Spherical protein particles and methods of making and using them
DK1425389T3 (da) * 2001-08-23 2012-01-30 Genmab As Interleukin-15-(IL-15)-specifikke humane antistoffer
US7247304B2 (en) * 2001-08-23 2007-07-24 Genmab A/S Methods of treating using anti-IL-15 antibodies
ATE518886T1 (de) * 2003-06-09 2011-08-15 Redox Reactive Reagents L L C Verfahren zur änderung der bindungsspezifität von plasmaproteinen durch oxidations- reduktionsreaktionen
US9557325B2 (en) * 2003-06-09 2017-01-31 Redox-Reactive Reagents Llc Method of altering the binding specificity of proteins by oxidation-reduction reactions
US7329353B2 (en) 2004-01-23 2008-02-12 Amgen Inc. LC/MS method of analyzing high molecular weight proteins
SG156672A1 (en) * 2004-10-22 2009-11-26 Amgen Inc Methods for refolding of recombinant antibodies
US7825223B2 (en) * 2005-06-17 2010-11-02 Janssen Alzheimer Immunotherapy Methods of purifying anti A β antibodies

Also Published As

Publication number Publication date
WO2006047340A3 (fr) 2007-07-05
MX2007004437A (es) 2007-06-20
NO20072571L (no) 2007-07-20
EA012162B1 (ru) 2009-08-28
AU2005299716B2 (en) 2012-09-06
NZ554520A (en) 2010-03-26
CA2584211A1 (fr) 2006-05-04
EP1805320A2 (fr) 2007-07-11
US20060194280A1 (en) 2006-08-31
JP5553963B2 (ja) 2014-07-23
CA2584211C (fr) 2014-07-08
JP2008520190A (ja) 2008-06-19
AU2005299716A1 (en) 2006-05-04
SG156672A1 (en) 2009-11-26
US7928205B2 (en) 2011-04-19
IL182626A0 (en) 2007-07-24
KR20070084483A (ko) 2007-08-24
BRPI0517457A (pt) 2008-10-07
EP1805320A4 (fr) 2009-09-16
EP1805320B1 (fr) 2014-09-03
JP2013055961A (ja) 2013-03-28
KR101370253B1 (ko) 2014-03-05
RU2007118954A (ru) 2008-11-27
WO2006047340A2 (fr) 2006-05-04
EA200700917A1 (ru) 2007-10-26

Similar Documents

Publication Publication Date Title
MA29027B1 (fr) Procedes de renaturation d'anticorps recombinants
NO2017058I1 (no) HPV 58 L1 protein
NO2017012I1 (no) HPV 45 L1 protein
CY2016035I2 (el) Θεραπευτικη χρηση αντισωματων anti-cs1
MA29014B1 (fr) Formulations d'anticorps
MA30684B1 (fr) Anticorps anti-mn et leurs procedes d'utilisation.
DE502004009199D1 (de) Kugelgelenkverbindung
LU91534I2 (fr) "Acide nicotinique/laropiprant"
ATE517887T1 (de) Neue 2-pyridincarbonsäureamidderivate
DE60218695D1 (de) Biosensoren und messverfahren
DE602005013417D1 (de) (biphenyl)carbonsäuren und derivate davon
DK1567112T3 (da) Thiazolidin-4-oner til at hæmme hYAK3-proteiner
DE602005025450D1 (de) Homokinetisches gelenk
ITTO20030640A1 (it) Apparato d'interfaccia uomo- macchina mediante
DE60332694D1 (de) Näherungssensor
IS8321A (is) Stöðug afbrigði tegaseródvetnismaleats
DE60216626D1 (de) Amperometrischer sensor
FR2875398B1 (fr) Implant articulaire d'interposition
DE602004009249D1 (de) Gleichlaufgelenk
FR2878850B1 (fr) Derives de l'inositol-1-phosphate
DE602004004206D1 (de) Gleichlaufgelenk
FR2842105B1 (fr) Localisation des genes impliques dans la canitie precoce
FR2858930B1 (fr) Unite mobile d'aspiration bronchique
ATE499348T1 (de) Stabiler polymorph von bifeprunoxmesilat
DE602004013668D1 (de) MPTP Affinitätsmarker